<DOC>
	<DOCNO>NCT00082212</DOCNO>
	<brief_summary>The purpose study determine overall response rate , time progression , 1 yr survival cetuximab patient ovarian primary peritoneal carcinoma .</brief_summary>
	<brief_title>A Study Patients With Persistent Recurrent Epithelial Ovarian Primary Peritoneal Carcinoma</brief_title>
	<detailed_description>To determine overall response rate cetuximab alone subject ovarian primary peritoneal carcinoma persistent recurrent disease follow 1-2 previous regimen chemotherapy . Potential relationship response , dose , occurence rash treatment subject stable disease initial 6 week treatment , time progression , 1 yr survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>subject must recurrent persistent epithelial ovarian primary peritoneal carcinoma . Histologic confirmation original primary tumor require . EGFR expression must positive determine outside reference lab Subjects must treatmentfree interval follow platinum &lt; 12 mo All subject must measurable disease baseline Subjects must least one recurrent lesion use assess response Recovery effect recent surgery , radiotherapy chemotherapy Subjects invasive malignancy ( include peritoneal mesothelioma ) Subjects unstable cardiac disease MI within 6 mos Subjects Acute hepatitis Subjects active uncontrolled infection A history prior cetuximab therapy target EGFR pathway prior history prior chimerized murine monoclonal antibody therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>ovarian</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>Persistent Recurrent Ovarian Cancer</keyword>
	<keyword>Primary Peritoneal Carcinoma</keyword>
</DOC>